Functions of the RNA editing enzyme ADAR1 and their relevance to human diseases

Genes

Volumn 7, Issue 12, 2016, Pages

  Song, Chunzi ^a   Sakurai, Masayuki ^a   Shiromoto, Yusuke ^a   Nishikura, Kazuko ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

ADAR1; Human diseases; Innate immunity; RNA editing

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE ACTING ON RNA 1; ADENOSINE DEAMINASE ACTING ON RNA 1 P150; ADENOSINE DEAMINASE ACTING ON RNA 2; DICER; DOUBLE STRANDED RNA; EXOGENOUS VIRAL DOUBLE STRANDED RNA; INOSINE; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; LONG UNTRANSLATED RNA; MEMBRANE PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 455; MITOCHONDRIAL ACTIVATION SIGNALING PROTEIN; PROTEIN KINASE R; RECEPTOR; RETINOIC ACID INDUCIBLE GENE I (RIG I) LIKE RECEPTOR; RNA BINDING PROTEIN; RNA INDUCED SILENCING COMPLEX; TRANSCRIPTOME; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AICARDI GOUTIERES SYNDROME; AUTOIMMUNE DISEASE; BILATERAL STRIATAL NECROSIS; BIOINFORMATICS; CELL SELF-RENEWAL; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SPECIFIC PATTERN; DOWN REGULATION; DYSCHROMATOSIS SYMMETRICA HEREDITARIA; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; GENERAL ASPECTS OF DISEASE; GENODERMATOSIS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; INNATE IMMUNITY; LIFE CYCLE; LUNG CANCER; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RETROPOSON; REVIEW; RNA EDITING; SIGNAL TRANSDUCTION; START CODON; STOP CODON; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; TYPE I INTERFERONOPATHY; UPREGULATION; VIRAL LIFE CYCLE; VIRAL PHENOMENA AND FUNCTIONS; VIRAL RECOGNITION;

EID: 85010408615     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes7120129     Document Type: Review

References (146)

1. Bass, B.L.; Weintraub, H. A developmentally regulated activity that unwinds RNA duplexes. Cell 1987, 48, 607-613.
2. Rebagliati, M.R.; Melton, D.A. Antisense RNA injections in fertilized frog eggs reveal an RNA duplex unwinding activity. Cell 1987, 48, 599-605.
3. Bass, B.L.; Weintraub, H. An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 1988, 55, 1089-1098.
4. Wagner, R.W.; Nishikura, K. Cell cycle expression of RNA duplex unwindase activity in mammalian cells. Mol. Cell. Biol. 1988, 8, 770-777.
5. Bass, B.L. RNA editing and hypermutation by adenosine deamination. Trends Biochem. Sci. 1997, 22, 157-162.
6. Polson, A.G.; Bass, B.L. Preferential selection of adenosines for modification by double-stranded RNA adenosine deaminase. EMBO J. 1994, 13, 5701-5711.
7. Lehmann, K.A.; Bass, B.L. Double-stranded RNA adenosine deaminases ADAR1 and ADAR2 have overlapping specificities. Biochemistry 2000, 39, 12875-12884.
8. Stefl, R.; Oberstrass, F.C.; Hood, J.L.; Jourdan, M.; Zimmermann, M.; Skrisovska, L.; Maris, C.; Peng, L.; Hofr, C.; Emeson, R.B. et al. The solution structure of the ADAR2 dsrbm-RNA complex reveals a sequence-specific readout of the minor groove. Cell 2010, 143, 225-237.
9. Barraud, P.; Allain, F.H. Adar proteins: Double-stranded RNA and z-DNA binding domains. Curr. Top. Microbiol. Immunol. 2012, 353, 35-60.
10. Kim, U.; Wang, Y.; Sanford, T.; Zeng, Y.; Nishikura, K. Molecular cloning of cdna for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc. Natl. Acad. Sci. USA 1994, 91, 11457-11461.
11. Melcher, T.; Maas, S.; Herb, A.; Sprengel, R.; Seeburg, P.H.; Higuchi, M. A mammalian RNA editing enzyme. Nature 1996, 379, 460-464.
12. Chen, C.X.; Cho, D.S.; Wang, Q.; Lai, F.; Carter, K.C.; Nishikura, K. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA 2000, 6, 755-767.
13. Melcher, T.; Maas, S.; Herb, A.; Sprengel, R.; Higuchi, M.; Seeburg, P.H. Red2, a brain-specific member of the RNA-specific adenosine deaminase family. J. Biol. Chem. 1996, 271, 31795-31798.
14. Poulsen, H.; Nilsson, J.; Damgaard, C.K.; Egebjerg, J.; Kjems, J. CRM1 mediates the export of ADAR1 through a nuclear export signal within the Z-DNA binding domain. Mol. Cell. Biol 2001, 21, 7862-7871.
15. George, C.X.; Samuel, C.E. Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible. Proc. Natl. Acad. Sci. USA 1999, 96, 4621-4626.
16. Strehblow, A.; Hallegger, M.; Jantsch, M.F. Nucleocytoplasmic distribution of human RNA-editing enzyme ADAR1 is modulated by double-stranded RNA-binding domains, a leucine-rich export signal, and a putative dimerization domain. Mol. Biol. Cell 2002, 13, 3822-3835.
17. Desterro, J.M.; Keegan, L.P.; Lafarga, M.; Berciano, M.T.; O’Connell, M.; Carmo-Fonseca, M. Dynamic association of RNA-editing enzymes with the nucleolus. J. Cell Sci. 2003, 116, 1805-1818.
18. Nishikura, K. A-to-I editing of coding and non-coding RNAs by ADARS. Nat. Rev. Mol. Cell Biol. 2016, 17, 83-96.
19. Nishikura, K. Functions and regulation of RNA editing by ADAR deaminases. Annu. Rev. Biochem. 2010, 79, 321-349.
20. Wang, Q.; Khillan, J.; Gadue, P.; Nishikura, K. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science 2000, 290, 1765-1768.
21. Yang, J.H.; Luo, X.; Nie, Y.; Su, Y.; Zhao, Q.; Kabir, K.; Zhang, D.; Rabinovici, R. Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to inflammation. Immunology 2003, 109, 15-23.
22. Liddicoat, B.J.; Chalk, A.M.; Walkley, C.R. ADAR1, inosine and the immune sensing system: Distinguishing self from non-self. Wiley Interdiscip. Rev. RNA 2016, 7, 157-172.
23. Yang, S.; Deng, P.; Zhu, Z.; Zhu, J.; Wang, G.; Zhang, L.; Chen, A.F.; Wang, T.; Sarkar, S.N.; Billiar, T.R. et al. Adenosine deaminase acting on RNA 1 limits RIG-I RNA detection and suppresses IFN production responding to viral and endogenous RNAs. J. Immunol. 2014, 193, 3436-3445.
24. Pestal, K.; Funk, C.C.; Snyder, J.M.; Price, N.D.; Treuting, P.M.; Stetson, D.B. Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development. Immunity 2015, 43, 933-944.
25. Liddicoat, B.J.; Piskol, R.; Chalk, A.M.; Ramaswami, G.; Higuchi, M.; Hartner, J.C.; Li, J.B.; Seeburg, P.H.; Walkley, C.R. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science 2015, 349, 1115-1120.
26. George, C.X.; Ramaswami, G.; Li, J.B.; Samuel, C.E. Editing of cellular self-RNAs by adenosine deaminase ADAR1 suppresses innate immune stress responses. J. Biol. Chem. 2016, 291, 6158-6168.
27. Patterson, J.B.; Samuel, C.E. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: Evidence for two forms of the deaminase. Mol. Cell. Biol. 1995, 15, 5376-5388.
28. Hartner, J.C.; Schmittwolf, C.; Kispert, A.; Muller, A.M.; Higuchi, M.; Seeburg, P.H. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J. Biol. Chem. 2004, 279, 4894-4902.
29. Hartner, J.C.; Walkley, C.R.; Lu, J.; Orkin, S.H. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat. Immunol. 2009, 10, 109-115.
30. XuFeng, R.; Boyer, M.J.; Shen, H.; Li, Y.; Yu, H.; Gao, Y.; Yang, Q.; Wang, Q.; Cheng, T. ADAR1 is required for hematopoietic progenitor cell survival via RNA editing. Proc. Natl. Acad. Sci. USA 2009, 106, 17763-17768.
31. Mannion, N.M.; Greenwood, S.M.; Young, R.; Cox, S.; Brindle, J.; Read, D.; Nellaker, C.; Vesely, C.; Ponting, C.P.; McLaughlin, P.J. et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 2014, 9, 1482-1494.
32. Crow, Y.J.; Chase, D.S.; Lowenstein Schmidt, J.; Szynkiewicz, M.; Forte, G.M.; Gornall, H.L.; Oojageer, A.; Anderson, B.; Pizzino, A.; Helman, G. et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am. J. Med. Genet. A 2015, 167A, 296-312.
33. Lebon, P.; Badoual, J.; Ponsot, G.; Goutieres, F.; Hemeury-Cukier, F.; Aicardi, J. Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy. J. Neurol. Sci. 1988, 84, 201-208.
34. Li, M.; Yang, L.; Li, C.; Jin, C.; Lai, M.; Zhang, G.; Hu, Y.; Ji, J.; Yao, Z. Mutational spectrum of the ADAR1 gene in dyschromatosis symmetrica hereditaria. Arch. Dermatol. Res. 2010, 302, 469-476.
35. Kondo, T.; Suzuki, T.; Mitsuhashi, Y.; Ito, S.; Kono, M.; Komine, M.; Akita, H.; Tomita, Y. Six novel mutations of the ADAR1 gene in patients with dyschromatosis symmetrica hereditaria: Histological observation and comparison of genotypes and clinical phenotypes. J. Dermatol. 2008, 35, 395-406.
36. Livingston, J.H.; Lin, J.P.; Dale, R.C.; Gill, D.; Brogan, P.; Munnich, A.; Kurian, M.A.; Gonzalez-Martinez, V.; De Goede, C.G.; Falconer, A. et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in adar1. J. Med. Genet. 2014, 51, 76-82.
37. Crow, Y.J.; Zaki, M.S.; Abdel-Hamid, M.S.; Abdel-Salam, G.; Boespflug-Tanguy, O.; Cordeiro, N.J.; Gleeson, J.G.; Gowrinathan, N.R.; Laugel, V.; Renaldo, F. et al. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. Neuropediatrics 2014, 45, 386-393.
38. Rice, G.I.; Kasher, P.R.; Forte, G.M.; Mannion, N.M.; Greenwood, S.M.; Szynkiewicz, M.; Dickerson, J.E.; Bhaskar, S.S.; Zampini, M.; Briggs, T.A. et al. Mutations in ADAR1 cause aicardi-goutieres syndrome associated with a type I interferon signature. Nat. Genet. 2012, 44, 1243-1248.
39. Hayashi, M.; Suzuki, T. Dyschromatosis symmetrica hereditaria. J. Dermatol. 2013, 40, 336-343.
40. Zhang, S.; Jiang, M.; Zhao, J. Two novel mutations in the DSRAD gene in two chinese pedigrees with dyschromatosis symmetrica hereditaria. Eur. J. Dermatol. 2013, 23, 782-785.
41. Zhu, C.Y.; Zhu, K.J.; Zhou, Y.; Fan, Y.M. A novel insertion mutation in the ADAR1 gene of a Chinese family with dyschromatosis symmetrica hereditaria. Genet. Mol. Res. 2013, 12, 2858-2862.
42. Liu, Q.; Wang, Z.; Wu, Y.; Cao, L.; Tang, Q.; Xing, X.; Ma, H.; Zhang, S.; Luo, Y. Five novel mutations in the ADAR1 gene associated with dyschromatosis symmetrica hereditaria. BMC Med. Genet. 2014.
43. Kono, M.; Matsumoto, F.; Suzuki, Y.; Suganuma, M.; Saitsu, H.; Ito, Y.; Fujiwara, S.; Moriwaki, S.; Matsumoto, K.; Matsumoto, N. et al. Dyschromatosis symmetrica hereditaria and aicardi-goutieres syndrome 6 are phenotypic variants caused by ADAR1 mutations. J. Invest. Dermatol. 2016, 136, 875-878.
44. Liu, Y.; Zhang, Z.; Mu, Y.; Xiong, F.; Chen, X.; Yang, H.; Yang, P.; Liu, L. Two novel mutations of the ADAR1 gene associated with dyschromatosis symmetrica hereditaria. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2016, 33, 173-176. (in Chinese).
45. Zhang, G.; Shao, M.; Li, Z.; Gu, Y.; Du, X.; Wang, X.; Li, M. Genetic spectrum of dyschromatosis symmetrica hereditaria in Chinese patients including a novel nonstop mutation in ADAR1 gene. BMC Med. Genet. 2016.
46. Cho, D.S.; Yang, W.; Lee, J.T.; Shiekhattar, R.; Murray, J.M.; Nishikura, K. Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J. Biol. Chem. 2003, 278, 17093-17102.
47. Valente, L.; Nishikura, K. RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions. J. Biol. Chem. 2007, 282, 16054-16061.
48. Vitali, P.; Scadden, A.D. Double-stranded RNAs containing multiple IU pairs are sufficient to suppress interferon induction and apoptosis. Nat. Struct. Mol. Biol. 2010, 17, 1043-1050.
49. Pfaller, C.K.; Mastorakos, G.M.; Matchett, W.E.; Ma, X.; Samuel, C.E.; Cattaneo, R. Measles virus defective interfering RNAs are generated frequently and early in the absence of C protein and can be destabilized by adenosine deaminase acting on RNA-1-like hypermutations. J. Virol. 2015, 89, 7735-7747.
50. Ward, S.V.; George, C.X.; Welch, M.J.; Liou, L.Y.; Hahm, B.; Lewicki, H.; de la Torre, J.C.; Samuel, C.E.; Oldstone, M.B. RNA editing enzyme adenosine deaminase is a restriction factor for controlling measles virus replication that also is required for embryogenesis. Proc. Natl. Acad. Sci. USA 2011, 108, 331-336.
51. Sarvestani, S.T.; Tate, M.D.; Moffat, J.M.; Jacobi, A.M.; Behlke, M.A.; Miller, A.R.; Beckham, S.A.; McCoy, C.E.; Chen, W.; Mintern, J.D. et al. Inosine-mediated modulation of rna sensing by toll-like receptor 7 (TLR7) and TLR8. J. Virol. 2014, 88, 799-810.
52. Macnaughton, T.B.; Li, Y.I.; Doughty, A.L.; Lai, M.M. Hepatitis delta virus RNA encoding the large delta antigen cannot sustain replication due to rapid accumulation of mutations associated with RNA editing. J. Virol. 2003, 77, 12048-12056.
53. Casey, J.L. Control of ADAR1 editing of hepatitis delta virus RNAs. Curr. Top. Microbiol. Immunol. 2012, 353, 123-143.
54. Taylor, D.R.; Puig, M.; Darnell, M.E.; Mihalik, K.; Feinstone, S.M. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J. Virol. 2005, 79, 6291-6298.
55. Cao, S.; Moss, W.; O'Grady, T.; Concha, M.; Strong, M.J.; Wang, X.; Yu, Y.; Baddoo, M.; Zhang, K.; Fewell, C. et al. New noncoding lytic transcripts derived from the epstein-barr virus latency origin of replication, orip, are hyperedited, bind the paraspeckle protein, NONO/p54nrb, and support viral lytic transcription. J. Virol. 2015, 89, 7120-7132.
56. Weiden, M.D.; Hoshino, S.; Levy, D.N.; Li, Y.; Kumar, R.; Burke, S.A.; Dawson, R.; Hioe, C.E.; Borkowsky, W.; Rom, W.N. et al. Adenosine deaminase acting on RNA-1 (ADAR1) inhibits HIV-1 replication in human alveolar macrophages. PLoS ONE 2014, 9, e108476.
57. Cachat, A.; Alais, S.; Chevalier, S.A.; Journo, C.; Fusil, F.; Dutartre, H.; Boniface, A.; Ko, N.L.; Gessain, A.; Cosset, F.L. et al. ADAR1 enhances HTLV-1 and HTLV-2 replication through inhibition of PKR activity. Retrovirology 2014.
58. Cuadrado, E.; Booiman, T.; van Hamme, J.L.; Jansen, M.H.; van Dort, K.A.; Vanderver, A.; Rice, G.I.; Crow, Y.J.; Kootstra, N.A.; Kuijpers, T.W. ADAR1 facilitates HIV-1 replication in primary CD4+ T cells. PLoS ONE 2015, 10, e0143613.
59. Phuphuakrat, A.; Kraiwong, R.; Boonarkart, C.; Lauhakirti, D.; Lee, T.H.; Auewarakul, P. Double-stranded RNA adenosine deaminases enhance expression of human immunodeficiency virus type 1 proteins. J. Virol. 2008, 82, 10864-10872.
60. Doria, M.; Neri, F.; Gallo, A.; Farace, M.G.; Michienzi, A. Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1 stimulates viral infection. Nucleic Acids Res. 2009, 37, 5848-5858.
61. Orecchini, E.; Federico, M.; Doria, M.; Arenaccio, C.; Giuliani, E.; Ciafre, S.A.; Michienzi, A. The ADAR1 editing enzyme is encapsidated into HIV-1 virions. Virology 2015, 485, 475-480.
62. Munir, M.; Berg, M. The multiple faces of proteinkinase R in antiviral defense. Virulence 2013, 4, 85-89.
63. George, C.X.; John, L.; Samuel, C.E. An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1). J. Interferon Cytokine Res. 2014, 34, 437-446.
64. John, L.; Samuel, C.E. Induction of stress granules by interferon and down-regulation by the cellular RNA adenosine deaminase ADAR1. Virology 2014, 454, 299-310.
65. Nie, Y.; Ding, L.; Kao, P.N.; Braun, R.; Yang, J.H. ADAR1 interacts with NF90 through double-stranded RNA and regulates NF90-mediated gene expression independently of Rna editing. Mol. Cell Biol. 2005, 25, 6956-6963.
66. Reichman, T.W.; Muniz, L.C.; Mathews, M.B. The RNA binding protein nuclear factor 90 functions as both a positive and negative regulator of gene expression in mammalian cells. Mol. Cell Biol. 2002, 22, 343-356.
67. Qin, Y.R.; Qiao, J.J.; Chan, T.H.; Zhu, Y.H.; Li, F.F.; Liu, H.; Fei, J.; Li, Y.; Guan, X.Y.; Chen, L. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res. 2014, 74, 840-851.
68. Chan, T.H.; Lin, C.H.; Qi, L.; Fei, J.; Li, Y.; Yong, K.J.; Liu, M.; Song, Y.; Chow, R.K.; Ng, V.H. et al. A disrupted RNA editing balance mediated by ADARs (adenosine deaminases that act on RNA) in human hepatocellular carcinoma. Gut 2014, 63, 832-843.
69. Han, L.; Diao, L.; Yu, S.; Xu, X.; Li, J.; Zhang, R.; Yang, Y.; Werner, H.M.; Eterovic, A.K.; Yuan, Y. et al. The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell 2015, 28, 515-528.
70. Wang, Y.; Zeng, Y.; Murray, J.M.; Nishikura, K. Genomic organization and chromosomal location of the human dsRNA adenosine deaminase gene: The enzyme for glutamate-activated ion channel RNA editing. J. Mol. Biol. 1995, 254, 184-195.
71. Anadon, C.; Guil, S.; Simo-Riudalbas, L.; Moutinho, C.; Setien, F.; Martinez-Cardus, A.; Moran, S.; Villanueva, A.; Calaf, M.; Vidal, A. et al. Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene 2015.
72. Yeo, J.; Goodman, R.A.; Schirle, N.T.; David, S.S.; Beal, P.A. RNA editing changes the lesion specificity for the DNA repair enzyme neil1. Proc. Natl. Acad. Sci. USA 2010, 107, 20715-20719.
73. Shimokawa, T.; Rahman, M.F.; Tostar, U.; Sonkoly, E.; Stahle, M.; Pivarcsi, A.; Palaniswamy, R.; Zaphiropoulos, P.G. RNA editing of the GLI1 transcription factor modulates the output of hedgehog signaling. RNA Biol. 2013, 10, 321-333.
74. Zipeto, M.A.; Jiang, Q.; Melese, E.; Jamieson, C.H. RNA rewriting, recoding, and rewiring in human disease. Trends Mol. Med. 2015, 21, 549-559.
75. Quelen, C.; Eloit, Y.; Noirot, C.; Bousquet, M.; Brousset, P. RNA editing in acute myeloid leukaemia with normal karyotype. Br. J. Haematol. 2016, 173, 788-790.
76. Beghini, A.; Ripamonti, C.B.; Peterlongo, P.; Roversi, G.; Cairoli, R.; Morra, E.; Larizza, L. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. Hum. Mol. Genet. 2000, 9, 2297-2304.
77. Gumireddy, K.; Li, A.; Kossenkov, A.V.; Sakurai, M.; Yan, J.; Li, Y.; Xu, H.; Wang, J.; Zhang, P.J.; Zhang, L. et al. The mRNA-edited form of GABRA3 suppresses GABRA3-mediated AKT activation and breast cancer metastasis. Nat. Commun. 2016.
78. Ohlson, J.; Pedersen, J.S.; Haussler, D.; Ohman, M. Editing modifies the GABA(A) receptor subunit α3. RNA 2007, 13, 698-703.
79. Daniel, C.; Veno, M.T.; Ekdahl, Y.; Kjems, J.; Ohman, M. A distant cis acting intronic element induces site-selective RNA editing. Nucleic Acids Res. 2012, 40, 9876-9886.
80. Han, S.W.; Kim, H.P.; Shin, J.Y.; Jeong, E.G.; Lee, W.C.; Kim, K.Y.; Park, S.Y.; Lee, D.W.; Won, J.K.; Jeong, S.Y. et al. RNA editing in RHOQ promotes invasion potential in colorectal cancer. J. Exp. Med. 2014, 211, 613-621.
81. Miyake, K.; Ohta, T.; Nakayama, H.; Doe, N.; Terao, Y.; Oiki, E.; Nagatomo, I.; Yamashita, Y.; Abe, T.; Nishikura, K. et al. CAPS1 RNA editing promotes dense core vesicle exocytosis. Cell Rep. 2016, 17, 2004-2014.
82. Kawahara, Y.; Grimberg, A.; Teegarden, S.; Mombereau, C.; Liu, S.; Bale, T.L.; Blendy, J.A.; Nishikura, K. Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J. Neurosci. 2008, 28, 12834-12844.
83. Niswender, C.M.; Herrick-Davis, K.; Dilley, G.E.; Meltzer, H.Y.; Overholser, J.C.; Stockmeier, C.A.; Emeson, R.B.; Sanders-Bush, E. RNA editing of the human serotonin 5-HT2C receptor. Alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 2001, 24, 478-491.
84. Di Narzo, A.F.; Kozlenkov, A.; Roussos, P.; Hao, K.; Hurd, Y.; Lewis, D.A.; Sibille, E.; Siever, L.J.; Koonin, E.; Dracheva, S. A unique gene expression signature associated with serotonin 2C receptor RNA editing in the prefrontal cortex and altered in suicide. Hum. Mol. Genet. 2014, 23, 4801-4813.
85. Anastasio, N.C.; Stutz, S.J.; Fox, R.G.; Sears, R.M.; Emeson, R.B.; DiLeone, R.J.; O’Neil, R.T.; Fink, L.H.; Li, D.; Green, T.A. et al. Functional status of the serotonin 5-HT2C receptor (5-HT2CR) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence. Neuropsychopharmacology 2014, 39, 370-382.
86. Lomeli, H.; Mosbacher, J.; Melcher, T.; Hoger, T.; Geiger, J.R.; Kuner, T.; Monyer, H.; Higuchi, M.; Bach, A.; Seeburg, P.H. Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science 1994, 266, 1709-1713.
87. Krampfl, K.; Schlesinger, F.; Zorner, A.; Kappler, M.; Dengler, R.; Bufler, J. Control of kinetic properties of GluR2 flop AMPA-type channels: Impact of R/G nuclear editing. Eur. J. Neurosci. 2002, 15, 51-62.
88. Vollmar, W.; Gloger, J.; Berger, E.; Kortenbruck, G.; Kohling, R.; Speckmann, E.J.; Musshoff, U. RNA editing (R/G site) and flip-flop splicing of the AMPA receptor subunit GluR2 in nervous tissue of epilepsy patients. Neurobiol. Dis. 2004, 15, 371-379.
89. Barbon, A.; Fumagalli, F.; Caracciolo, L.; Madaschi, L.; Lesma, E.; Mora, C.; Carelli, S.; Slotkin, T.A.; Racagni, G.; Di Giulio, A.M. et al. Acute spinal cord injury persistently reduces R/G RNA editing of AMPA receptors. J. Neurochem. 2010, 114, 397-407.
90. Penn, A.C.; Balik, A.; Greger, I.H. Steric antisense inhibition of AMPA receptor Q/R editing reveals tight coupling to intronic editing sites and splicing. Nucleic Acids Res. 2013, 41, 1113-1123.
91. Bonini, D.; Filippini, A.; La Via, L.; Fiorentini, C.; Fumagalli, F.; Colombi, M.; Barbon, A. Chronic glutamate treatment selectively modulates AMPA RNA editing and ADAR expression and activity in primary cortical neurons. RNA Biol. 2015, 12, 43-53.
92. Mahajan, S.S.; Thai, K.H.; Chen, K.; Ziff, E. Exposure of neurons to excitotoxic levels of glutamate induces cleavage of the RNA editing enzyme, adenosine deaminase acting on RNA 2, and loss of GluR2 editing. Neuroscience 2011, 189, 305-315.
93. Sailer, A.; Swanson, G.T.; Perez-Otano, I.; O'Leary, L.; Malkmus, S.A.; Dyck, R.H.; Dickinson-Anson, H.; Schiffer, H.H.; Maron, C.; Yaksh, T.L. et al. Generation and analysis of GluR5(Q636R) kainate receptor mutant mice. J. Neurosci. 1999, 19, 8757-8764.
94. Egebjerg, J.; Heinemann, S.F. Ca2+ permeability of unedited and edited versions of the kainate selective glutamate receptor GluR6. Proc. Natl. Acad. Sci. USA 1993, 90, 755-759.
95. Kohler, M.; Burnashev, N.; Sakmann, B.; Seeburg, P.H. Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: Diversity by RNA editing. Neuron 1993, 10, 491-500.
96. Riedmann, E.M.; Schopoff, S.; Hartner, J.C.; Jantsch, M.F. Specificity of ADAR-mediated RNA editing in newly identified targets. RNA 2008, 14, 1110-1118.
97. Matthews, M.M.; Thomas, J.M.; Zheng, Y.; Tran, K.; Phelps, K.J.; Scott, A.I.; Havel, J.; Fisher, A.J.; Beal, P.A. Structures of human ADAR2 bound to dsRNA reveal base-flipping mechanism and basis for site selectivity. Nat. Struct. Mol. Biol. 2016, 23, 426-433.
98. Wong, S.K.; Sato, S.; Lazinski, D.W. Substrate recognition by ADAR1 and ADAR2. RNA 2001, 7, 846-858.
99. Nishikura, K.; Yoo, C.; Kim, U.; Murray, J.M.; Estes, P.A.; Cash, F.E.; Liebhaber, S.A. Substrate specificity of the dsRNA unwinding/modifying activity. EMBO J. 1991, 10, 3523-3532.
100. Macbeth, M.R.; Lingam, A.T.; Bass, B.L. Evidence for auto-inhibition by the N terminus of hADAR2 and activation by dsRNA binding. RNA 2004, 10, 1563-1571.
101. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509-524.
102. Nemlich, Y.; Greenberg, E.; Ortenberg, R.; Besser, M.J.; Barshack, I.; Jacob-Hirsch, J.; Jacoby, E.; Eyal, E.; Rivkin, L.; Prieto, V.G. et al. Microrna-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J. Clin. Invest. 2013, 123, 2703-2718.
103. Zhang, L.; Yang, C.S.; Varelas, X.; Monti, S. Altered RNA editing in 30 UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors. Sci. Rep. 2016.
104. Shoshan, E.; Mobley, A.K.; Braeuer, R.R.; Kamiya, T.; Huang, L.; Vasquez, M.E.; Salameh, A.; Lee, H.J.; Kim, S.J.; Ivan, C. et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat. Cell Biol. 2015, 17, 311-321.
105. Li, N.F.; Gemenetzidis, E.; Marshall, F.J.; Davies, D.; Yu, Y.; Frese, K.; Froeling, F.E.; Woolf, A.K.; Feakins, R.M.; Naito, Y. et al. RhoC interacts with integrin a5ß1 and enhances its trafficking in migrating pancreatic carcinoma cells. PLoS ONE 2013, 8, e81575.
106. Islam, M.; Sharma, S.; Teknos, T.N. RhoC regulates cancer stem cells in head and neck squamous cell carcinoma by overexpressing IL-6 and phosphorylation of STAT3. PLoS ONE 2014, 9, e88527.
107. Rosenthal, D.T.; Zhang, J.; Bao, L.; Zhu, L.; Wu, Z.; Toy, K.; Kleer, C.G.; Merajver, S.D. Rhoc impacts the metastatic potential and abundance of breast cancer stem cells. PLoS ONE 2012, 7, e40979.
108. Gembarska, A.; Luciani, F.; Fedele, C.; Russell, E.A.; Dewaele, M.; Villar, S.; Zwolinska, A.; Haupt, S.; de Lange, J.; Yip, D. et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med. 2012, 18, 1239-1247.
109. McEvoy, J.; Ulyanov, A.; Brennan, R.; Wu, G.; Pounds, S.; Zhang, J.; Dyer, M.A. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS ONE 2012, 7, e42739.
110. Liang, H.Q.; Wang, R.J.; Diao, C.F.; Li, J.W.; Su, J.L.; Zhang, S. The PTTG1-targeting miRNAs mir-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget 2015, 6, 29413-29427.
111. Formosa, A.; Markert, E.K.; Lena, A.M.; Italiano, D.; Finazzi-Agro, E.; Levine, A.J.; Bernardini, S.; Garabadgiu, A.V.; Melino, G.; Candi, E. MicroRNAs, mir-154, mir-299-5p, mir-376a, mir-376c, mir-377, mir-381, mir-487b, mir-485-3p, mir-495 and mir-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 2014, 33, 5173-5182.
112. Garcia-Lopez, J.; Hourcade Jde, D.; Del Mazo, J. Reprogramming of microRNAs by adenosine-to-inosine editing and the selective elimination of edited microRNA precursors in mouse oocytes and preimplantation embryos. Nucleic Acids Res. 2013, 41, 5483-5493.
113. Kawahara, Y.; Zinshteyn, B.; Chendrimada, T.P.; Shiekhattar, R.; Nishikura, K. RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer-TRBP complex. EMBO Rep. 2007, 8, 763-769.
114. Iizasa, H.; Wulff, B.E.; Alla, N.R.; Maragkakis, M.; Megraw, M.; Hatzigeorgiou, A.; Iwakiri, D.; Takada, K.; Wiedmer, A.; Showe, L. et al. Editing of Epstein-Barr virus-encoded BART6 micrornas controls their dicer targeting and consequently affects viral latency. J. Biol. Chem. 2010, 285, 33358-33370.
115. Kawahara, Y.; Zinshteyn, B.; Sethupathy, P.; Iizasa, H.; Hatzigeorgiou, A.G.; Nishikura, K. Redirection of silencing targets by adenosine-to-inosine editing of mirnas. Science 2007, 315, 1137-1140.
116. Heale, B.S.; Keegan, L.P.; McGurk, L.; Michlewski, G.; Brindle, J.; Stanton, C.M.; Caceres, J.F.; O’Connell, M.A. Editing independent effects of ADARs on the miRNA/siRNA pathways. EMBO J. 2009, 28, 3145-3156.
117. Bahn, J.H.; Ahn, J.; Lin, X.; Zhang, Q.; Lee, J.H.; Civelek, M.; Xiao, X. Genomic analysis of ADAR1 binding and its involvement in multiple RNA processing pathways. Nat. Commun. 2015.
118. Chen, T.; Xiang, J.F.; Zhu, S.; Chen, S.; Yin, Q.F.; Zhang, X.O.; Zhang, J.; Feng, H.; Dong, R.; Li, X.J. et al. Adar1 is required for differentiation and neural induction by regulating microRNA processing in a catalytically independent manner. Cell Res. 2015, 25, 459-476.
119. Galore-Haskel, G.; Nemlich, Y.; Greenberg, E.; Ashkenazi, S.; Hakim, M.; Itzhaki, O.; Shoshani, N.; Shapira-Fromer, R.; Ben-Ami, E.; Ofek, E. et al. A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. Oncotarget 2015, 6, 28999-29015.
120. Ota, H.; Sakurai, M.; Gupta, R.; Valente, L.; Wulff, B.E.; Ariyoshi, K.; Iizasa, H.; Davuluri, R.V.; Nishikura, K. ADAR1 forms a complex with dicer to promote microRNA processing and RNA-induced gene silencing. Cell 2013, 153, 575-589.
121. Ramaswami, G.; Zhang, R.; Piskol, R.; Keegan, L.P.; Deng, P.; O’Connell, M.A.; Li, J.B. Identifying RNA editing sites using RNA sequencing data alone. Nat. Methods 2013, 10, 128-132.
122. Bazak, L.; Haviv, A.; Barak, M.; Jacob-Hirsch, J.; Deng, P.; Zhang, R.; Isaacs, F.J.; Rechavi, G.; Li, J.B.; Eisenberg, E. et al. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res. 2014, 24, 365-376.
123. Lev-Maor, G.; Sorek, R.; Levanon, E.Y.; Paz, N.; Eisenberg, E.; Ast, G. RNA-editing-mediated exon evolution. Genome Biol. 2007.
124. Sakurai, M.; Yano, T.; Kawabata, H.; Ueda, H.; Suzuki, T. Inosine cyanoethylation identifies a-to-i rna editing sites in the human transcriptome. Nat. Chem Biol 2010, 6, 733-740.
125. Ivanov, A.; Memczak, S.; Wyler, E.; Torti, F.; Porath, H.T.; Orejuela, M.R.; Piechotta, M.; Levanon, E.Y.; Landthaler, M.; Dieterich, C. et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015, 10, 170-177.
126. Hansen, T.B.; Jensen, T.I.; Clausen, B.H.; Bramsen, J.B.; Finsen, B.; Damgaard, C.K.; Kjems, J. Natural RNA circles function as efficient microRNA sponges. Nature 2013, 495, 384-388.
127. Hansen, T.B.; Kjems, J.; Damgaard, C.K. Circular RNA and mir-7 in cancer. Cancer Res. 2013, 73, 5609-5612.
128. Liang, H.; Landweber, L.F. Hypothesis: RNA editing of microRNA target sites in humans? RNA 2007, 13, 463-467.
129. Borchert, G.M.; Gilmore, B.L.; Spengler, R.M.; Xing, Y.; Lanier, W.; Bhattacharya, D.; Davidson, B.L. Adenosine deamination in human transcripts generates novel microrna binding sites. Hum. Mol. Genet. 2009, 18, 4801-4807.
130. Stellos, K.; Gatsiou, A.; Stamatelopoulos, K.; Perisic Matic, L.; John, D.; Lunella, F.F.; Jae, N.; Rossbach, O.; Amrhein, C.; Sigala, F. et al. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling hur-mediated post-transcriptional regulation. Nat. Med. 2016.
131. Daniel, C.; Silberberg, G.; Behm, M.; Ohman, M. Alu elements shape the primate transcriptome by cis-regulation of RNA editing. Genome Biol 2014, 15, R28.
132. Osenberg, S.; Paz Yaacov, N.; Safran, M.; Moshkovitz, S.; Shtrichman, R.; Sherf, O.; Jacob-Hirsch, J.; Keshet, G.; Amariglio, N.; Itskovitz-Eldor, J. et al. Alu sequences in undifferentiated human embryonic stem cells display high levels of A-to-I RNA editing. PLoS ONE 2010, 5, e11173.
133. Rinn, J.L.; Chang, H.Y. Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 2012, 81, 145-166.
134. Salameh, A.; Lee, A.K.; Cardo-Vila, M.; Nunes, D.N.; Efstathiou, E.; Staquicini, F.I.; Dobroff, A.S.; Marchio, S.; Navone, N.M.; Hosoya, H. et al. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc. Natl. Acad. Sci. USA 2015, 112, 8403-8408.
135. Orecchini, E.; Doria, M.; Antonioni, A.; Galardi, S.; Ciafre, S.A.; Frassinelli, L.; Mancone, C.; Montaldo, C.; Tripodi, M.; Michienzi, A. ADAR1 restricts LINE-1 retrotransposition. Nucleic Acids Res. 2016.
136. Miki, Y.; Nishisho, I.; Horii, A.; Miyoshi, Y.; Utsunomiya, J.; Kinzler, K.W.; Vogelstein, B.; Nakamura, Y. Disruption of the APC gene by a retrotransposal insertion of L1 sequence in a colon cancer. Cancer Res. 1992, 52, 643-645.
137. Iskow, R.C.; McCabe, M.T.; Mills, R.E.; Torene, S.; Pittard, W.S.; Neuwald, A.F.; Van Meir, E.G.; Vertino, P.M.; Devine, S.E. Natural mutagenesis of human genomes by endogenous retrotransposons. Cell 2010, 141, 1253-1261.
138. Beck, C.R.; Garcia-Perez, J.L.; Badge, R.M.; Moran, J.V. Line-1 elements in structural variation and disease. Annu. Rev. Genomics Hum. Genet. 2011, 12, 187-215.
139. Paz-Yaacov, N.; Bazak, L.; Buchumenski, I.; Porath, H.T.; Danan-Gotthold, M.; Knisbacher, B.A.; Eisenberg, E.; Levanon, E.Y. Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors. Cell Rep. 2015, 13, 267-276.
140. Cenci, C.; Barzotti, R.; Galeano, F.; Corbelli, S.; Rota, R.; Massimi, L.; Di Rocco, C.; O’Connell, M.A.; Gallo, A. Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J. Biol. Chem. 2008, 283, 7251-7260.
141. Ma, C.H.; Chong, J.H.; Guo, Y.; Zeng, H.M.; Liu, S.Y.; Xu, L.L.; Wei, J.; Lin, Y.M.; Zhu, X.F.; Zheng, G.G. Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias. Biochem. Biophys. Res. Commun. 2011, 406, 245-251.
142. Chan, T.H.; Qamra, A.; Tan, K.T.; Guo, J.; Yang, H.; Qi, L.; Lin, J.S.; Ng, V.H.; Song, Y.; Hong, H. et al. Adar-mediated RNA editing predicts progression and prognosis of gastric cancer. Gastroenterology 2016, 151, 637-650.
143. Dou, N.; Yu, S.; Ye, X.; Yang, D.; Li, Y.; Gao, Y. Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling. Oncotarget 2016.
144. Zipeto, M.A.; Court, A.C.; Sadarangani, A.; Delos Santos, N.P.; Balaian, L.; Chun, H.J.; Pineda, G.; Morris, S.R.; Mason, C.N.; Geron, I. et al. ADAR1 activation drives leukemia stem cell self-renewal by impairing Let-7 biogenesis. Cell Stem Cell 2016.
145. Jiang, Q.; Crews, L.A.; Barrett, C.L.; Chun, H.J.; Court, A.C.; Isquith, J.M.; Zipeto, M.A.; Goff, D.J.; Minden, M.; Sadarangani, A. et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 2013, 110, 1041-1046.
146. Yang, B.; Hu, P.; Lin, X.; Han, W.; Zhu, L.; Tan, X.; Ye, F.; Wang, G.; Wu, F.; Yin, B. et al. PTBP1 induces ADAR1 p110 isoform expression through IRES-like dependent translation control and influences cell proliferation in gliomas. Cell Mol. Life Sci. 2015, 72, 4383-4397.